<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956447</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002281</org_study_id>
    <nct_id>NCT02956447</nct_id>
  </id_info>
  <brief_title>Administration of Kisspeptin in Patients With Hyperprolactinemia</brief_title>
  <official_title>Administration of Kisspeptin in Patients With Hyperprolactinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to explore the use of exogenous pulsatile kisspeptin as a
      therapeutic alternative for patients with hyperprolactinemia who are intolerant to current
      therapies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2017</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of Luteinizing Hormone (LH) pulses between days 1 and 7 (Arms: Kisspeptin Bolus and Baseline)</measure>
    <time_frame>Evaluated at Visits 1 and 2 (Days 1 and 7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in follicle size in mm by ultrasound over the course of kisspeptin administration (Arm: Pulsatile Kisspeptin)</measure>
    <time_frame>Evaluated at Visits 10, 13, 15,17 (Days 7, 10, 12, and 14 kisspeptin administration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovulation after high dose kisspeptin as evidenced by ultrasound (Arm: Pulsatile Kisspeptin)</measure>
    <time_frame>Evaluated on day 34</time_frame>
    <description>Ultrasound evidence of corpus luteum will be used to determine if ovulation occurred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolactin</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estrogen</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progesterone</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Aspartate Aminotransferase (AST)/alanine aminotransferase (ALT) (Arm: Pulsatile kisspeptin)</measure>
    <time_frame>Evaluated on the first and last day of the study, an average of 3 months between each evaluation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Creatinine</measure>
    <time_frame>Evaluated on the first and last day of the study, an average of 3 months between each evaluation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Complete Blood Count (CBC)</measure>
    <time_frame>Evaluated on the first and last day of the study, an average of 3 months between each evaluation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Evaluated on the first and last day of the study, an average of 3 months between each evaluation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Thyroid-Stimulating Hormone (TSH)</measure>
    <time_frame>Evaluated on the first and last day of the study, an average of 3 months between each evaluation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Evaluated on the first and last day of the study, an average of 3 months between each evaluation</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hyperprolactinemia</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Kisspeptin Bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of kisspeptin 112-121 0.24 nmol/kg intravenously (IV); 10 boluses in a 10 hour period. One bolus of GnRH at hour 11. Blood sampling every 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blood sampling every 10 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulsatile kisspeptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over 14 days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kisspeptin 112-121</intervention_name>
    <description>0.313 Âµg/kg IV</description>
    <arm_group_label>Kisspeptin Bolus</arm_group_label>
    <arm_group_label>Pulsatile kisspeptin</arm_group_label>
    <other_name>Metastin 45-54</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin Releasing Hormone (GnRH)</intervention_name>
    <description>0.075 ug/kg IV</description>
    <arm_group_label>Kisspeptin Bolus</arm_group_label>
    <other_name>gonadotropin-releasing hormone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:

          -  Confirmed diagnosis by elevated levels of prolactin measured via blood test and MRI
             imaging confirming no pituitary abnormality or a microprolactinoma (&lt;10 mm). Patients
             with a macroprolactinoma will be excluded.

          -  no history of a medication reaction requiring emergency medical care,

          -  no illicit drug use,

          -  no excessive alcohol consumption (&lt;10 drinks/week),

          -  not currently seeking fertility, breastfeeding or pregnant

          -  Physical Examination:

               -  normal blood pressure, (systolic BP &lt; 140 mm Hg, diastolic &lt; 90 mm Hg).

          -  Laboratory Studies:

               -  white blood cell, platelet counts, and TSH between 90% of the lower limit and
                  110% of the upper limit of the reference range,

               -  hemoglobin no less than 0.5 gm/dL below the lower limit of the reference range
                  for normal women,

               -  BUN, creatinine, AST, ALT not elevated,

               -  negative serum human chorionic gonadotropin (hCG) pregnancy test at the time of
                  screening (additional urine pregnancy test will be conducted prior to drug
                  administration).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Seminara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Addie Davies</last_name>
    <phone>617-724-8764</phone>
    <email>mghkisspeptinresearch@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Addie Davies</last_name>
      <phone>617-724-8764</phone>
      <email>mghkisspeptinresearch@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Stephanie B. Seminara, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Harvard Medical School; Associate Chief for Research and Administration, Reproductive Endocrine Unit, Massachusetts General Hospital</investigator_title>
  </responsible_party>
  <keyword>Kisspeptin</keyword>
  <keyword>Hyperprolactinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Hyperprolactinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After primary results are published, the authors will provide individual participant data upon request as long as it does not conflict with state or institutional regulations</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

